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The growing prevalence of metabolic diseases, such as obesity and diabetes, are putting
a high strain on global healthcare systems as well as increasing the demand for efficient
treatment strategies. More than 360 million people worldwide are suffering from type
2 diabetes (T2D) and, with the current trends, the projection is that 10% of the global
adult population will be affected by 2030. In light of the systemic properties of metabolic
diseases as well as the interconnected nature of metabolism, it is necessary to begin
taking a holistic approach to study these diseases. Human genome-scale metabolic
models (GEMs) are topological and mathematical representations of cell metabolism and
have proven to be valuable tools in the area of systems biology. Successful applications
of GEMs include the process of gaining further biological and mechanistic understanding
of diseases, finding potential biomarkers, and identifying new drug targets. This review
will focus on the modeling of human metabolism in the field of obesity and diabetes,
showing its vast range of applications of clinical importance as well as point out future
challenges.
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INTRODUCTION
Metabolism, the set of chemical reactions taking place in a
cell, plays an important part in maintaining cell functionality
by responding to various perturbations, sustaining the produc-
tion of essential molecules and cell components, breaking down
compounds for energy production and catabolizing xenobiotics.
The drivers behind these typically thousands of reactions are
enzymes, whose concentrations are controlled by several levels of
regulation, affected both by the cell type and its surrounding envi-
ronment. Due to the central role of metabolism it is not surprising
that its dysfunction is associated with several complex diseases, of
which prominent examples are obesity and diabetes. The severity
of this is further emphasized by the fact that more than 360 mil-
lion people are suffering from type 2 diabetes (T2D) and that in
2011 this disease contributed to more than 3.5 million deaths in
middle-income countries (Whiting et al., 2011; Scully, 2012). The
prevalence of T2D has not stopped increasing and the incidence
among young adults and children is rising for each decade (Chen
et al., 2012). In 2030, it is projected that 552million people, corre-
sponding to 10% of the global adult population, will suffer from
T2D (Whiting et al., 2011).
T2D is characterized by impaired insulin secretion and insulin
resistance, mainly manifested in liver, skeletal muscle, and adi-
pose tissue, leading to malfunctioning glucose homeostasis and
metabolism. This complex metabolic disease is associated with
a multitude of risk factors including physical inactivity, diet, gut
microbiome composition, obesity, aging and genetic components
(Doria et al., 2008). The cellular events characteristic of T2D
and obesity, but also influenced by different treatment strategies
(including physical activity, diet, calorie restriction, and surgery),
are eventually manifested through changes in metabolism. It is of
course highly relevant to elucidate mechanistic explanations for
the disease, as well as for existing treatments, in order to gain
further biological understanding, identify new biomarkers, and
find potential drug targets. Due to the interconnected nature of
metabolism and the fact that a cell acts as a system, it is logical to
take a holistic approach to investigate these issues.
In this context, genome-scale metabolic models (GEMs) that
are in silico representations of metabolism at the genome level,
have emerged as a key tool in the field of systems biology
(Mardinoglu et al., 2013b). Further on, the increasing generation
and availability of high-throughput omics data (e.g., transcrip-
tomics or proteomics) is not only pushing the need of GEMs
as well as enabling advanced analysis (Patil and Nielsen, 2005;
Yizhak et al., 2010), but is also driving improvements in the recon-
struction process itself (Shlomi et al., 2008; Agren et al., 2012).
Several authors have reviewed human GEMs and their grow-
ing scope of applications in general (Bordbar and Palsson, 2012;
Mardinoglu and Nielsen, 2012). In this review we focus specifi-
cally on the modeling of humanmetabolism in the field of obesity
and diabetes.
HUMAN GENOME-SCALE METABOLIC MODELS
Historically, GEMs were initially developed to study microbial
metabolism, starting with the reconstruction of Haemophilus
influenza metabolism (Edwards and Palsson, 1999). Since then,
GEMs for many pathogens and industrially relevant organisms
have been produced (Oberhardt et al., 2009). With a shift in focus
to human metabolism, early attempts to human GEMs include
the mitochondrial metabolic network (Vo et al., 2004). In 2007,
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two global human metabolic network reconstructions, Recon
1 (Duarte et al., 2007) and the Edinburgh Human Metabolic
Network (EHMN) (Ma et al., 2007), were published. The EHMN
was later updated with information about cellular compartments
(Hao et al., 2010). In 2012, the Human Metabolic Reaction
(HMR) database was created (Agren et al., 2012), encompassing
information from Recon 1 and EHMN, as well as from the Kyoto
Encyclopedia of Genes andGenomes (KEGG) database (Kanehisa
et al., 2012), and later updated with extensive lipid metabolism
(Mardinoglu et al., 2013a). In 2013, the metabolic reconstruction
Recon 2 was published (Thiele et al., 2013). These generic human
GEMs have been shown to havemany applications, including e.g.,
the study of disease comorbidity (Lee et al., 2008), cancer drug
target discovery (Agren et al., 2012; Jerby and Ruppin, 2012),
biomarkers for inborn errors of metabolism (Shlomi et al., 2009)
and brain energy metabolism in Alzheimer’s disease (Lewis et al.,
2010).
THE STRUCTURE OF GEMs
The conceptual structure of a GEM is summarized in Figure 1A.
In its simplest form a GEM is a list of mass-balanced reac-
tions, describing the conversion of substrate metabolites into
FIGURE 1 | An overview of human genome-scale metabolic models
(GEMs) and their applications in the field of obesity and diabetes.
(A) A metabolic network is in simple terms a list of the chemical reactions
taking place in a cell. These reactions can be grouped into pathways and
associated with a particular cellular compartment (e.g., mitochondria).
Metabolites can be passed between compartments through transport
reactions. Each reaction can be associated to its corresponding
enzyme-coding genes, and together all the reactions provide a network
structure connecting metabolites, reactions and genes. (B) The metabolic
network can be represented mathematically by the stoichiometric matrix,
S, containing the stoichiometric coefficients of the metabolites (rows)
taking part in each reaction (columns). Under the constraint based
modeling framework it is assumed that the metabolite concentrations are
unchanged (Sv = 0). Further on, additional constraints can be put on the
flux vector, v, to find capable and probable flux distributions. Alternatively,
flux balance analysis (FBA) can be used to find a flux vector that optimizes
an objective function (e.g., maximize ATP production). (C) GEMs have
been used to study obesity- and diabetes-related conditions. Clinical data
can be used to construct context specific GEMs from generic ones. This
type of data can also be integrated and analyzed, in combination or
separately, with the GEMs, in a topological or simulation based manner.
(D) This enables e.g., the identification of transcriptionally affected
reactions and pathways as well as metabolic hotspots, or the comparison
of simulation results in terms of network capabilities.
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product metabolites. In addition, reactions can be associated to
cellular compartments (e.g., cytoplasm or mitochondria), thus
partitioning the metabolic network into sections connected only
through transport reactions. When the information is available,
enzyme-coding genes are associated with their corresponding
reactions. As such, the GEM constitutes a knowledge-base of
human metabolism and its information along with the pro-
vided network topology can be used to analyze and interpret
external high-throughput data. Apart from this, GEMs can be
used for simulating how metabolism operates at different condi-
tions using the constraint-based modeling framework described
next.
CONSTRAINT-BASEDMODELING AND SIMULATION
Constraint-based modeling is used to simulate and predict
metabolic phenotypes (Bordbar and Palsson, 2012). In order to
do this, the GEM is expressed in mathematical terms in form of a
stoichiometric matrix, S, where rows correspond to metabolites
and columns represent reactions (Figure 1B). For a particular
reaction, or column of S, the metabolites taking part in the reac-
tion are denoted with their stoichiometric coefficient (negative
for substrates and positive for products), all other values are
set to zero. Under the constraint-based modeling framework, it
is assumed that the concentrations of all metabolites are con-
stant, meaning that the sum of fluxes of the reactions where the
metabolite is consumed has to be equal to the sum of fluxes of
the reactions where the metabolite is produced. Mathematically,
this can be written as Sv = 0, where v is a vector of fluxes
for each reaction. This system is underdetermined, i.e., there
are many possible flux vectors that solve the system. However,
the solution space can be shrunk by applying constraints on v,
based on current physiochemical and biological knowledge. A
common approach is to use linear programming to find a flux
vector that optimizes an objective function (e.g., to maximize a
specific flux), given the constraints on v and the condition Sv = 0.
This approach is called flux balance analysis, FBA (Orth et al.,
2010).
CELL-TYPE SPECIFIC GEMs
Generic GEMs (such as Recon 1, EHMN and HMR) are also
useful resources for new reconstructions, in particular when con-
sidering cell-type specific networks. Manual reconstruction is
very laborious and because of this much interest has been put into
algorithmic approaches for automated or semi-automated GEM
reconstruction (Shlomi et al., 2008; Blazier and Papin, 2012). An
example of this is the INIT algorithm (Agren et al., 2012), and the
GIMME algorithm (Becker and Palsson, 2008), which has been
used in studies included in this review and is described briefly in
the next section. In general these kinds of algorithms start with
a generic GEM, representing the superset of human metabolism,
and based on cell or tissue specific omics data (e.g., transcrip-
tomics or proteomics) the metabolic network is reduced into a
subset of reactions, representing the metabolic capabilities of a
specific cell type. These cell-type specific networks can then be
used for analysis of metabolic features of specific cell types as well
as analyzing differences inmetabolism, e.g., between a healthy cell
and a cancer cell.
STUDYING OBESITY AND DIABETES USING HUMAN GEMs
Falling within the scope of this review, 10 studies using GEMs in
the area of obesity and diabetes were identified and are summa-
rized in Table 1. High-throughput omics data (gene expression,
proteomics, and metabolite profiles) as well as physiological and
pathological knowledge can be integrated, in combination or
separately, with GEMs in order to unravel the underlying mech-
anisms of obesity and diabetes (Figure 1C). This information
has also been used to construct context-specific metabolic net-
works, better representing the key cell types involved in these
Table 1 | Overview of studies using human GEMs to study obesity and diabetes.
References Topic/condition Tissue(s) Source network(s) Modified network(s)
TOPOLOGY BASED ANALYSIS AND DATA INTEGRATION
Duarte et al., 2007 Gastric bypass surgery Skeletal muscle Recon 1 No modification
Capel et al., 2009 Calorie restriction Adipose tissue Recon 1, EHMN No modification
Deo et al., 2010 Impaired glucose
tolerance
Blood Recon 1 Metabolic reaction network (MRN)
Zelezniak et al., 2010 Type 2 diabetes Skeletal muscle Recon 1, EHMN No modification
Mutch et al., 2011 Calorie restriction Adipose tissue EHMN No modification
Morine et al., 2011 Metabolic syndrome and
n3 PUFA diet
Adipose tissue EHMN Transformation to an enzyme-centric
network
CONSTRAINT BASED MODELING AND SIMULATION
Thiele et al., 2005 Diabetes Heart Mitochondrial Extended mitochondrial
Becker and Palsson, 2008 Gastric bypass,
glucose/insulin infusion,
obesity
Skeletal muscle Recon 1 Myocytes in different conditions
Bordbar et al., 2011 Type 2 diabetes Liver, skeletal muscle,
adipose tissue
Recon 1 Hepatocyte, myocyte, adipocyte
Mardinoglu et al., 2013a Obesity Adipose tissue HMR Adipocyte
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diseases: adipocytes (fat cells), hepatocytes (liver cells), and
myocytes (skeletal muscle cells). Roughly, the following studies
have either used network topology to contextualize omics data
or used specific GEMs to simulate and evaluate flux capabilities
(Figure 1D).
EXPLOITING METABOLIC NETWORK TOPOLOGY—PUTTING CONTENT
INTO CONTEXT
Topological analysis of the generic human metabolic networks
Recon 1 and EHMN has been exploited to dissect the com-
plexity of metabolism in many studies. In fact, one of the first
applications of Recon 1 was to map human skeletal muscle
gene expression data on to the network, in order to interpret
the metabolic effects of gastric bypass surgery (Duarte et al.,
2007). Both surgically induced calorie restriction, as in this exam-
ple, and calorie-restricted diet, as in several examples below,
are used as weight loss treatment for obesity. Weight loss in
obese individuals, in turn, is known to improve insulin sen-
sitivity and to have a positive effect on metabolism (Reaven,
2005). In their study Duarte et al. (2007) found that anaero-
bic metabolism was up-regulated and that oxidative phospho-
rylation was down-regulated one year after surgery, suggesting
that the effects of calorie restriction remain even after weight
stabilization.
An alternative way to interpret transcriptome data is to shift
the focus from reactions to metabolites. Patil and Nielsen (2005)
described one such algorithm which uses the gene-enzyme-
reaction-metabolite relationship and scores each metabolite by
combining the p-values of its connected genes, based on gene
expression data. This enables the identification of what the
authors refer to as reporter metabolites, i.e., metabolic hotspots
or metabolites around which important transcriptional changes
occur.
Capel et al. (2009) used reporter metabolite analysis to
detect differences in adipose tissue of obese subjects under-
going a dietary intervention program (calorie restriction fol-
lowed by weight stabilization). The authors used both Recon
1 and EHMN to define the gene-metabolite connections and
identified acyl-CoA, CoA, acetyl-CoA, NADP+/NADPH, and
ubiquinol/ubiquinone as reporter metabolites, surrounded by
down-regulated enzymes during calorie restriction and showing
a reversed pattern during weight stabilization. In a similar study
the EHMN was used to identify reporter metabolites as can-
didate biomarkers for successful weight maintenance. This was
done by comparing adipose tissue gene expression of subjects
maintaining weight with those regaining weight, after undergo-
ing calorie restriction (Mutch et al., 2011). Reporter metabolites
for the weight maintainers, during calorie restriction, were in
agreement with the previous study by Capel et al. (2009). In
particular the weight maintainers showed a more coordinate
response to calorie restriction, compared to weight regainers,
shown by a highly connected sub-network of significant enzymes
and metabolites.
Zelezniak et al. (2010) used reporter metabolite analysis
together with Recon 1 and EHMN to find metabolic signatures
of T2D in skeletal muscle, using two publically available gene
expression datasets. Metabolites from the TCA cycle, oxidative
phosphorylation and lipid metabolism were identified as reporter
metabolites, several of these being potential novel biomarkers
for T2D. Further on, for the genes associated to the reporter
metabolites, the authors found enrichment of transcription fac-
tor binding motifs belonging to the CREB, NRF1, and PPAR
families.
In order to investigate the effect of n-3 polyunsaturated fatty
acid (PUFA) intake on adipose tissue gene expression among
subjects with metabolic syndrome, Morine et al. (2011) con-
verted the EHMN to an enzyme-centric directed network, so
that two enzymes were connected if a product metabolite of
the first enzyme was used as a substrate by the second. Further
on, by determining the co-expression of each pair of connected
enzymes, the authors were able to identify metabolically feasible
co-expressed paths (i.e., paths of connected metabolite conver-
sions, where each conversion is co-expressed with the next one
in the sequence). In particular, co-expressed paths containing
enzymes whose expression was affected by n-3 PUFA intake were
identified and inversely correlated to a urinary biomarker of
oxidative stress. Their approach also identified pathway overlap
in the metabolism of inositol phosphate derivatives, lipids and
fatty acids, important in the context of dietary induced signaling
cascades.
The previously mentioned studies used GEMs to analyze tran-
scriptome data, however, other high-throughput data can also
be contextualized with the aid of metabolic networks. Deo et al.
(2010) analyzed metabolite profiles from blood of subjects with
normal (NGT) and impaired glucose tolerance (IGT) undergoing
an oral glucose tolerance test (OGTT). The authors constructed
a so called metabolic reaction network, MRN, based on Recon
1 and 737 additional transport reactions. In MRN, metabolites
are nodes and two metabolites are connected if they take part
in the same enzymatic or transport reaction. Integrating the
MRN with the metabolite data, the authors were able to identify
active subnetworks, i.e., metabolic regions affected by changing
metabolite levels during an OGTT. Using tissue specific GEMs
(Shlomi et al., 2008) they found that the subnetworks were active
in kidney and liver metabolism. They also point out the impor-
tance of differences in solute carrier activities in response to
glucose.
CELL-TYPE SPECIFIC MODELS AND FLUX SIMULATION
The examples in the previous section reflect how the topology
of GEMs can be used to interpret high-throughput data in a
metabolic context. Besides this, GEMs have also been applied as
models for simulation of metabolic fluxes in the study of diabetes
and obesity. An important application in this context is to use
clinical data of exchange fluxes to predict intracellular metabolic
fluxes.
One of the first studies using GEMs in the context of dia-
betes was that of Thiele et al. (2005). The authors used a
previously published mitochondrial metabolic network of the
human cardiomyocyte (Vo et al., 2004) and expanded it by
including ketone body degradation, with the purpose to study
the effects of diabetes and different diets. In order to sim-
ulate diabetic conditions, the authors applied metabolic con-
straints on the fluxes through selected exchange reactions based
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on experimental measurements (increased mitochondrial fatty
acid uptake, reduced glucose uptake, and increased ketone body
uptake). Given these constraints, the authors calculated possible
solutions to Sv = 0, resulting in a set of flux vectors, or can-
didate metabolic network states, which enabled the authors to
investigate capable and most probable fluxes through selected
reactions. Their analysis showed that network stoichiometry,
as opposed to active enzyme levels, could explain the reduced
flux through mitochondrial pyruvate dehydrogenase in dia-
betes.
When modeling human metabolism it is of course impor-
tant to consider cell-type specific metabolism. Becker and Palsson
(2008) developed an algorithm, Gene Inactivity Moderated by
Metabolism and Expression (GIMME), that uses gene expression
data and a generic GEM, together with objective functions, to
produce context-specific functional GEMs. Simply put, GIMME
assumes that transcript levels correlate to reaction fluxes and thus
removes reactions from the generic network where the corre-
sponding enzymes show low expression. However, the new GEM
is required to be able to perform certain characteristic metabolic
functions (specified by the objective functions and FBA) and
to ensure this, previously removed reactions are allowed to be
reintroduced in a way that minimizes the deviation between
the expression data and the resulting model. The authors used
Recon 1 and GIMME to produce 42 context-specific models of
human myocytes using three gene expression datasets (gastric
bypass, glucose/insulin infusion, and obesity) and the metabolic
requirement of at least sub-optimal ATP producing capabilities.
They found that the metabolic networks of a patient before and
after surgery or glucose/insulin infusion are more similar to each
other than to networks of other patients. They also observed that
patients after glucose/insulin infusion show higher ATP produc-
tion, as expected.
Bordbar et al. (2011) used Recon 1 as a starting point to con-
struct cell-type specific GEMs for adipocytes, hepatocytes, and
myocytes and additionally connected these models by introduc-
ing a joint blood compartment. This multi-tissue GEM was used
as input to GIMME, together with transcription data from adi-
pose, liver, and skeletal muscle tissue of healthy obese and T2D
obese subjects. The resulting context-specific models were used to
compare themetabolic reaction activity of the two subject groups.
Using this approach, the authors found several known differences
between healthy obese and T2D obese subjects. They also identi-
fied cysteine dioxygenase, which was found inactive in the adipose
of diabetic subjects, as a potential reason for elevated levels of
cytotoxic cysteine and decreased levels of taurine, an important
metabolite in diabetes and shown to reduce diabetic symptoms
(Hansen, 2001).
Mardinoglu et al. (2013a) extended the HMR with extensive
lipid metabolism and used it, together with adipocyte specific
proteomics data (Uhlen et al., 2010), to construct a functional
adipocyte GEM. Constraints on the fluxes were added from clin-
ical data (fatty acid transport as well as glucose and amino acid
uptake rates) from lean and obese subjects in order to simulate
lipid droplet formation using FBA. The authors found that lean
subjects show larger dynamics in lipid droplet formation com-
pared to obese subjects. Further on, feasible and most probable
metabolic flux distributions (given Sv = 0 and the constraints
on v) were calculated using a random sampling algorithm (Bordel
et al., 2010) in order to find reactions with changing fluxes
between obese and lean subjects. By correlating these results
with gene expression data from the same subjects, the authors
were able to identify reactions likely to be transcriptionally regu-
lated, including down-regulation of glucose and fatty acid uptake,
oxidative phosphorylation, beta-oxidation, fatty acidmetabolism,
tricarboxylic acid cycle, and beta-alanine metabolism in obese
subjects.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Human GEMs have proven to be very valuable in studies of
metabolic disorders, such as obesity and diabetes. Through com-
pilation of years of community research the human GEMs
encompass state of the art genome-wide metabolic knowledge. As
such, they provide a biologically meaningful context for the inter-
pretation of various high-throughput datasets. As shown in many
of the studies discussed in this review, topology-based analysis
can successfully identify results that are not evident from tra-
ditional analyses. An example of this is the study by Deo et al.
(2010) where active metabolic regions could be identified using
Recon 1, but not when applying traditional pathway enrichment
methods.
One of the strengths of GEMs is their ability to generate new
hypotheses and predictions, as shown in many of the previously
mentioned studies. As for any modeling approach, validation
of the results is of course essential. In particular, since GEMs
are represented on a genome-wide scale they integrate well with
omics data. This means that predictions made by the GEMs,
such as reporter metabolites as candidate biomarkers, can be
validated on transcript, protein as well as metabolite levels. In
general, the previously mentioned studies tend to support their
modeling results with evidence in the literature. A high correla-
tion with experimental data is of course confirming GEMs as a
relevant modeling approach. However, to strengthen the actual
novel predictions the ambition should be to validate and con-
firm these through subsequent experiments, e.g., as in Frezza
et al. (2011). With the wider use of GEMs there are likely to
come many studies in the future that will evaluate model predic-
tions.
Several challenges still remain in the area of human metabolic
modeling. One is to improve constraint-based modeling tech-
niques for human metabolism, in particular the issue of formu-
lating valid metabolic objective functions that reflect healthy and
disease phenotypes in a manner that leads to correct biologi-
cal conclusions. Further on, the predictive power will always be
limited by the content of the used GEM. Thus, advances in the
reconstruction procedure, both of generic and specific GEMs,
will be important in order to sustain the production of up-
to-date networks. Since the pathology of obesity and diabetes
is highly dependent of the interplay between liver, adipose and
muscle tissue, the next step in metabolic modeling should be to
focus on model integration, both in terms of capturing interac-
tions of cell types within each tissue, as well as between tissues.
First steps include the multi-tissue model (Bordbar et al., 2011)
summarized in this review, as well as the metabolic interaction of
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different brain cells (Lewis et al., 2010), both which are encour-
aging for future developments. Finally, although metabolism
is a major component of obesity and diabetes, it is impor-
tant to consider the impact of additional biological processes.
A long-term future direction should be to integrate differ-
ent models (such as GEMs, signaling pathways, and gene reg-
ulatory networks) to better recapitulate these pathologies at
multiple length and time scales. Promising conceptual work
on integrating models includes the whole-cell model by Karr
et al. (2012) and the pharmacokinetic model by Krauss et al.
(2012).
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